<DOC>
	<DOC>NCT00196404</DOC>
	<brief_summary>This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and elevated urinary frequency</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder</brief_title>
	<detailed_description>This is a multi-center, randomized, placebo-controlled study to compare two doses of DR-3001 to placebo for a 12-week treatment period. The overall duration of patient participation will be for approximately 19 weeks. Patients will be required to keep a daily diary record of study medication use and incontinence episodes</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>Diagnosis of overactive bladder and incontinence for at least 6 months Using birth control or menopausal Willing to discontinue current medication for overactive bladder Pregnant or given birth in the last 6 months Three or more urinary tract infections a year Uncontrolled glaucoma, hypertension, diabetes or myasthenia gravis History of bladder cancer, ulcerative colitis or severe constipation Any contraindication to vaginal delivery systems</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>urge incontinence</keyword>
	<keyword>urinary incontinence</keyword>
</DOC>